Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Mendus AB (publ) (IMMU.ST)
Stockholm, SE
Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB (publ) until its name change in June 2022, specializes in developing immunotherapies and vaccines designed to prevent cancer recurrence. Its primary investigational compound, ilixadencel, is currently progressing through a Phase II MERECA clinical study for kidney cancer, alongside Phase I/II trials targeting liver cancer and gastrointestinal stromal tumors. Additionally, the company is advancing DCP-001, which is undergoing Phase II ADVANCE-II clinical research for acute myeloid leukemia and Phase I/II ALISON trials for ovarian cancers. Mendus maintains research partnerships with PCI Biotech Holding ASA to explore novel cancer vaccination approaches and with the Icahn School of Medicine at Mount Sinai. Founded in 2002, Mendus AB is headquartered in Stockholm, Sweden.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.48% | +31.14% | +12.83% | +24.07% | -4.47% | +3.64% | +20.56% | -77.00% | -94.43% | -98.79% | -16.71% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%— Q1'26: -100.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+17.8% Q1'26: +44.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-21.7% Q1'26: -20.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+7.3% Q1'26: +23.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.28× Q1'26: -0.19× (vs Q1'25)
| Metric |
Dec 2017 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 1 Rev. Ana. 3 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 67.3K (-100.0%)
|
3.00M
est: 1.07M (+180.8%)
|
28.49M
est: 31.60M (-9.8%)
|
—
est: 4.08M (-100.0%)
|
—
est: 6.00M (-100.0%)
|
2.50M
2.21M – 2.79M
-58.3% YoY
|
47.40M
46.92M – 47.88M
+1,796.0% YoY
|
114.00M
112.85M – 115.15M
+140.5% YoY
|
| EBITDA |
-80.63M
est: -13.5K (-599,052.9%)
|
-128.67M
est: -213.3K (-60,215.6%)
|
-97.85M
est: -6.32M (-1,448.3%)
|
-120.66M
est: -815.0K (-14,705.0%)
|
-120.26M
est: -1.20M (-9,921.3%)
|
-500.0K
-558.7K – -441.3K
+58.3% YoY
|
-9.48M
-9.58M – -9.38M
-1,796.0% YoY
|
-22.80M
-23.03M – -22.57M
-140.5% YoY
|
| EBIT |
-80.06M
est: -13.5K (-594,862.9%)
|
-133.52M
est: -213.3K (-62,488.1%)
|
-101.22M
est: -6.32M (-1,501.7%)
|
-127.18M
est: -815.0K (-15,504.9%)
|
-120.26M
est: -1.20M (-9,921.3%)
|
-500.0K
-558.7K – -441.3K
+58.3% YoY
|
-9.48M
-9.58M – -9.38M
-1,796.0% YoY
|
-22.80M
-23.03M – -22.57M
-140.5% YoY
|
| Net Income |
-80.34M
est: -1.39B (+94.2%)
|
-136.99M
est: -591.32M (+76.8%)
|
-101.62M
est: -177.89M (+42.9%)
|
-128.40M
est: -135.70M (+5.4%)
|
-113.26M
est: -100.21M (-13.0%)
|
-79.33M
-79.78M – -78.89M
+20.8% YoY
|
-16.65M
-28.48M – -4.82M
+79.0% YoY
|
—
— – —
+100.0% YoY
|
| SGA |
61.53M
est: 97.81M (-37.1%)
|
48.88M
est: 1.55B (-96.8%)
|
37.05M
est: 45.93B (-99.9%)
|
34.07M
est: 5.92B (-99.4%)
|
35.20M
est: 8.72B (-99.6%)
|
3.63B
3.21B – 4.06B
-58.3% YoY
|
68.90B
68.20B – 69.60B
+1,796.0% YoY
|
165.71B
164.03B – 167.39B
+140.5% YoY
|
| EPS |
-2.85
est: -28.60 (+90.0%)
|
-0.63
est: -12.16 (+94.8%)
|
-4.40
est: -3.41 (-29.1%)
|
-2.64
est: -2.60 (-1.5%)
|
-2.17
est: -1.92 (-13.0%)
|
-1.52
-1.53 – -1.51
+20.8% YoY
|
-0.26
-0.55 – -0.09
+82.9% YoY
|
—
— – —
+100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-12 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-11 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Erik Manting | Chief Executive Officer | — | — |
| Lotta Ferm | Chief Financial Officer | — | female |
| Tariq Mughal | Chief Medical & Scientific Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IMMU.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
